Other Information.
+Added: Rule 10b5-1 Trading Arrangements
+Added: On August 27, 2024 , Sean McCarthy , CEO , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 200,000 shares of the Company’s common stock until December 31, 2025 .
CytomX Therapeutics, Inc.
5 unchanged sentences
Specimen Common Stock Certificate
−Removed: Amendment No.1 to the Collaboration and License Agreement effective as of June 28, 2024 by and between CytomX Therapeutics, Inc.
−Removed: and Regeneron Pharmaceuticals, Inc.
+Added: Amendment No.
+Added: 2 to Open Market Sales Agreement, dated as of August 9, 2024, by and between CytomX Therapeutics, Inc.
+Added: and Jefferies LLC.
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
9 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
−Removed: Certain confidential portions of this exhibit have been omitted from this exhibit.
* The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of CytomX Therapeutics, Inc.
3 unchanged sentences
CytomX Therapeutics, Inc.
−Removed: August 8, 2024
+Added: November 7, 2024
Chief Executive Officer and Chairman
(Principal Executive Officer)
−Removed: August 8, 2024
+Added: November 7, 2024
/s/ Christopher W.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.